• Vivek Verma, Gillian L Drury, Marc Parisien, Ayşe N Özdağ Acarli, Tho-Alfakar Al-Aubodah, Anastasia Nijnik, Xia Wen, Nicol Tugarinov, Maria Verner, Richie Klares, Alexander Linton, Emerson Krock, Carlos E Morado Urbina, Bendik Winsvold, Lars G Fritsche, Egil A Fors, Ciriaco Piccirillo, Arkady Khoutorsky, Camilla I Svensson, Mary A Fitzcharles, Pablo M Ingelmo, Nicole F Bernard, Franck P Dupuy, Nurcan Üçeyler, Claudia Sommer, Irah L King, Carolina B Meloto, Luda Diatchenko, and HUNT-All In Pain.
• Alan Edwards Centre for Research on Pain, McGill University, Montréal, QC, Canada.
• Pain. 2022 Jul 1; 163 (7): e821e836e821-e836.

AbstractThe pathophysiology of fibromyalgia syndrome (FMS) remains elusive, leading to a lack of objective diagnostic criteria and targeted treatment. We globally evaluated immune system changes in FMS by conducting multiparametric flow cytometry analyses of peripheral blood mononuclear cells and identified a natural killer (NK) cell decrease in patients with FMS. Circulating NK cells in FMS were exhausted yet activated, evidenced by lower surface expression of CD16, CD96, and CD226 and more CD107a and TIGIT. These NK cells were hyperresponsive, with increased CCL4 production and expression of CD107a when co-cultured with human leukocyte antigen null target cells. Genetic and transcriptomic pathway analyses identified significant enrichment of cell activation pathways in FMS driven by NK cells. Skin biopsies showed increased expression of NK activation ligand, unique long 16-binding protein, on subepidermal nerves of patients FMS and the presence of NK cells near peripheral nerves. Collectively, our results suggest that chronic activation and redistribution of circulating NK cells to the peripheral nerves contribute to the immunopathology associated with FMS.Copyright © 2021 International Association for the Study of Pain.

22 keywords...

hide…